WINREVAIR
Biological
Merck Sharp & Dohme LLC
Total Payments
$40.6M
Transactions
7,228
Doctors
3,000
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $40.6M | 7,227 | 2,999 |
| 2022 | $31.44 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $39.5M | 438 | 97.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $415,228 | 128 | 1.0% |
| Travel and Lodging | $344,603 | 695 | 0.8% |
| Food and Beverage | $171,197 | 5,580 | 0.4% |
| Consulting Fee | $118,710 | 85 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $44,645 | 16 | 0.1% |
| Education | $4,276 | 286 | 0.0% |
Payments by Type
Research
$39.5M
438 transactions
General
$1.1M
6,790 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection Fraction HFpEF | Merck Sharp & Dohme LLC | $16.3M | 0 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension PAH World Health Organization WHO Functional Class FC III or FC IV at High Risk of Mortality | Merck Sharp & Dohme LLC | $8.1M | 0 |
| A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients | Merck Sharp & Dohme LLC | $5.1M | 0 |
| An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH | Merck Sharp & Dohme LLC | $4.2M | 0 |
| STUDY NAME#Effect of sotatercept on central cardiopulmonary performance and peripheral O2 transport during exercise - a comprehensive, paired cardiopulmonary exercise study with partial vasodilator withdrawal | Merck Sharp & Dohme LLC | $3.5M | 0 |
| A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept MK-7962 in Children from 1 to Less Than 18 Years of Age With PAH on Standard of Care | Merck Sharp & Dohme LLC | $1.2M | 0 |
| A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection Fraction HFpEF | Merck Sharp & Dohme LLC | $610,494 | 0 |
| STUDY NAME#Crosstalk of activin , bone morphogenetic protein with traditional pulmonary arterial hypertension pathways | Merck Sharp & Dohme LLC | $201,295 | 0 |
| STUDY NAME#129Xenon MR Imaging and Spectroscopy Response to Sotatercept in Pulmonary Arterial Hypertension | Merck Sharp & Dohme LLC | $149,995 | 0 |
| STUDY NAME#Effect of sotatercept on central cardiopulmonary performance and peripheral O2 transport during exercise - a comprehensive paired cardiopulmonary exercise study with partial vasodilator withdrawal | Merck Sharp & Dohme LLC | $99,622 | 0 |
| A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7962 Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension PAH on Standard of Care | Merck Sharp & Dohme LLC | $72,944 | 0 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Aterial Hypertension PAH Therapy for the Treatment of PAH | Merck Sharp & Dohme LLC | $2,351 | 0 |
Top Doctors Receiving Payments for WINREVAIR — Page 119
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Texarkana, TX | $13.64 | 1 |
| , FNP | Nurse Practitioner | Texarkana, TX | $13.64 | 1 |
| , FNP-C | Family | Texarkana, TX | $13.64 | 1 |
| , D.O | Internal Medicine | Linwood, NJ | $13.61 | 1 |
| , APRN-CNP | Family | San Antonio, TX | $13.59 | 1 |
| , MD | Cardiovascular Disease | Great Falls, MT | $13.57 | 1 |
| , M.D. F.C.C.P | Pulmonary Disease | Lafayette, LA | $13.54 | 1 |
| , APRN | Acute Care | Hutchinson, KS | $13.52 | 1 |
| , AGACNP | Acute Care | Hutchinson, KS | $13.52 | 1 |
| , M.D | Cardiovascular Disease | Lima, OH | $13.50 | 1 |
| , DO | Cardiovascular Disease | Lima, OH | $13.50 | 1 |
| , DO | Cardiovascular Disease | Lima, OH | $13.50 | 1 |
| , PA-C | Medical | Lima, OH | $13.50 | 1 |
| Natalie Lammers | Physician Assistant | Lima, OH | $13.50 | 1 |
| , DO | Cardiovascular Disease | Lima, OH | $13.50 | 1 |
| , PA-C | Physician Assistant | Lima, OH | $13.50 | 1 |
| , M.D | Critical Care Medicine | Warwick, RI | $13.45 | 1 |
| , NP-C | Family | Savannah, GA | $13.40 | 1 |
| , M.D | Internal Medicine | Roseville, CA | $13.40 | 1 |
| , ACNP | Acute Care | Memphis, TN | $13.38 | 1 |
| , DO | Pulmonary Disease | Memphis, TN | $13.38 | 1 |
| , M.D | Sleep Medicine | Memphis, TN | $13.38 | 1 |
| , MD | Pulmonary Disease | Marlton, NJ | $13.37 | 1 |
| , MB CHB | Pulmonary Disease | Marlton, NJ | $13.37 | 1 |
| , APN | Nurse Practitioner | Marlton, NJ | $13.37 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme LLC $40.6M
Product Information
- Type Biological
- Total Payments $40.6M
- Total Doctors 3,000
- Transactions 7,228
About WINREVAIR
WINREVAIR is a biological associated with $40.6M in payments to 3,000 healthcare providers, recorded across 7,228 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme LLC.
Payment data is available from 2022 to 2024. In 2024, $40.6M was paid across 7,227 transactions to 2,999 doctors.
The most common payment nature for WINREVAIR is "Unspecified" ($39.5M, 97.3% of total).
WINREVAIR is associated with 12 research studies, including "A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection Fraction HFpEF" ($16.3M).